Primary lung adenocarcinoma occurring in a PTEN related syndrome (Cowden's disease): Routine EGFR sequencing also highlights two rare somatic mutations S768I and V769L

Lung Cancer

Volumn 79, Issue 3, 2013, Pages 318-320

  Boespflug, Amélie ^a,b   Couraud, Sébastien ^a,b   Bringuier, Pierre Paul ^c   Isaac, Sylvie ^a   Gérinière, Laurence ^a   Perrot, Emilie ^a   Edery, Patrick ^a,b   Durieu, Isabelle ^a,b   Souquet, Pierre Jean ^a  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Cowden syndrome; EGFR; Lung cancer; PTEN related syndrome

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKERATIN 7; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; THYROID TRANSCRIPTION FACTOR 1;

ADULT; ARTICLE; BRAIN EDEMA; CANCER STAGING; CASE REPORT; CODON; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; COWDEN SYNDROME; EXON; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE SEQUENCE; HAMARTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG LOBE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHLEBITIS; PRIORITY JOURNAL; SMOKING; SOMATIC MUTATION; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; CHROMOSOME DISORDERS; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; FEMALE; GERM-LINE MUTATION; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; LUNG NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SERINE; SIGNAL TRANSDUCTION; VALINE;

EID: 84873171934     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.11.020     Document Type: Article

References (18)

1. Farooq A., Walker L.G., Bowling J., Audisio R.A. Cowden syndrome. Cancer Treat Rev 2010, 36(8):577-583.
2. Scheper M.A., Nikitakis N.G., Sarlani E., Sauk J.J., Meiller T.F. Cowden syndrome: report of a case with immunohistochemical analysis and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006, 101(May (5)):625-631.
3. Asahina H., Yamasaki K., Kinoshita I., Yokouchi H., Dosaka-Akita H., Nishimura M. Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L. Lung Cancer 2006, 54(3):419-422.
4. Solli P., Rossi G., Carbognani P., Spaggiari L., Gabrielli M., Tincani G., et al. Pulmonary abnormalities in Cowden's disease. J Cardiovasc Surg (Torino) 1999, 40(5):753-755. [Abstract].
5. Tan D., Li Q., Deeb G., Ramnath N., Slocum H.K., Brooks J., et al. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Hum Pathol 2003, 34:597-604.
6. Nelen M.R., Kremer H., Konings I.B., Schoute F., van Essen A.J., Koch R., et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet 1999, 7(3):267-273.
7. Hollander M.C., Blumenthal G.M., Dennis P.A. PTEN loss in the continuum of common cancers rare syndromes and mouse models. Nature Reviews 2011, 11:289-301.
8. Marsit C.J., Zheng S., Aldape K., Hinds P.W., Nelson H.H., Wiencke J.K., et al. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol 2005, 36(7):768-776.
9. Soria J.C., Lee H.Y., Lee J.I., Wang L., Issa J.P., Kemp B.L., et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 2002, 8:1178-1184.
10. Zhang J.G., Wang J.J., Zhao F., Liu Q., Jiang K., Yang G.H. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta 2010, 411(11-12):846-852.
11. Li G., Zhao J., Peng X., Liang J., Deng X., Chen Y. The mechanism involved in the loss of PTEN expression in NSCLC tumor cells. Biochem Biophys Res Commun 2012, 418(February (3)):547-552.
12. Zhang L., Liu T., Liu H., Gao J., Gu C. Loss and inactivation of PTEN/MMAC1/TEP1 gene in lung cancer. Zhonghua Bing Li Xue Za Zhi 2000, 29(2):85-88. [Abstract].
13. Suzuki A., Nakano T., Mak T.W., Sasaki T. Portrait of PTEN: messages from mutant mice. Cancer Sci 2008, 99(February (2)):209-213.
14. Iwanaga K., Yang Y., Raso M.G., Ma L., Hanna A.E. PTEN inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a Mouse Model of Lung Cancer. Cancer Res 2008, 68:1119-1127.
15. Yanagi S., Kishimoto H., Kawahara K., Sasaki T., Sasaki M., Nishio M., et al. Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice. J Clin Invest 2007, 117(October (10)):2929-2940.
16. Yamamoto C., Basaki Y., Kawahara A., Nakashima K., Kage M., Izumi H., et al. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res 2010, 70(21):8715-8725.
17. Masago K., Fujita S., Irisa K., Kim Y.H., Ichikawa M., Mio T., et al. Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation (S768I). Jpn J Clin Oncol 2010, 40(11):1105-1109.
18. Yang J.C., Shih J.Y., Su W.C., Hsia T.C., Tsai C.M., Ou S.H., Yu C.J., Chang G.C., Ho C.L., Sequist L.V., Dudek A.Z., Shahidi M., Cong X.J., Lorence R.M., Yang P.C., Miller V.A. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012, 13(May (5)):539-548.